TWI605048B - Novel pyrrolopyrimidine compounds or salts thereof, and pharmaceutical compositions containing the same, in particular, prophylactic and / or therapeutic agents for tumors and the like based on the inhibition of NAE - Google Patents

Novel pyrrolopyrimidine compounds or salts thereof, and pharmaceutical compositions containing the same, in particular, prophylactic and / or therapeutic agents for tumors and the like based on the inhibition of NAE Download PDF

Info

Publication number
TWI605048B
TWI605048B TW104120451A TW104120451A TWI605048B TW I605048 B TWI605048 B TW I605048B TW 104120451 A TW104120451 A TW 104120451A TW 104120451 A TW104120451 A TW 104120451A TW I605048 B TWI605048 B TW I605048B
Authority
TW
Taiwan
Prior art keywords
group
ethynyl
methyl
amino
compound
Prior art date
Application number
TW104120451A
Other languages
English (en)
Chinese (zh)
Other versions
TW201625629A (zh
Inventor
Takashi Mizutani
Chihoko Yoshimura
Hitomi Kondo
Makoto Kitade
Shuichi Ohkubo
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of TW201625629A publication Critical patent/TW201625629A/zh
Application granted granted Critical
Publication of TWI605048B publication Critical patent/TWI605048B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW104120451A 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compounds or salts thereof, and pharmaceutical compositions containing the same, in particular, prophylactic and / or therapeutic agents for tumors and the like based on the inhibition of NAE TWI605048B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014129740 2014-06-24
JP2015024785 2015-02-10

Publications (2)

Publication Number Publication Date
TW201625629A TW201625629A (zh) 2016-07-16
TWI605048B true TWI605048B (zh) 2017-11-11

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104120451A TWI605048B (zh) 2014-06-24 2015-06-24 Novel pyrrolopyrimidine compounds or salts thereof, and pharmaceutical compositions containing the same, in particular, prophylactic and / or therapeutic agents for tumors and the like based on the inhibition of NAE

Country Status (21)

Country Link
US (2) US9963456B2 (enExample)
EP (1) EP3103802B1 (enExample)
JP (1) JP6192741B2 (enExample)
KR (1) KR101947289B1 (enExample)
CN (1) CN106661031B (enExample)
AU (1) AU2015281155B9 (enExample)
BR (1) BR112016025835B1 (enExample)
CA (1) CA2946833C (enExample)
DK (1) DK3103802T3 (enExample)
ES (1) ES2656772T3 (enExample)
HU (1) HUE037266T2 (enExample)
MX (1) MX2016015015A (enExample)
MY (1) MY183327A (enExample)
NO (1) NO3103802T3 (enExample)
PH (1) PH12016502130A1 (enExample)
PL (1) PL3103802T3 (enExample)
PT (1) PT3103802T (enExample)
RU (1) RU2658008C2 (enExample)
SG (1) SG11201608441YA (enExample)
TW (1) TWI605048B (enExample)
WO (1) WO2015199136A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
US10865208B2 (en) 2016-11-11 2020-12-15 Millennium Pharmaceuticals, Inc. ATG7 inhibitors and the uses thereof
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する2’-デオキシ-7-デアザプリンヌクレオシド誘導体
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108822145B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种磺酰胺类化合物及其制备方法和应用
CN108640945B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种酰胺类化合物及其制备方法与应用
WO2020014541A2 (en) * 2018-07-13 2020-01-16 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1848718B1 (en) * 2005-02-04 2012-08-01 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
US7989430B2 (en) * 2005-12-06 2011-08-02 Regents Of The University Of Minnesota Antibacterial agents
MY171289A (en) 2006-02-02 2019-10-07 Millennium Pharm Inc Inhibitors of e1 activating enzymes
WO2012061551A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
JP2014501772A (ja) 2011-01-07 2014-01-23 レオ ファーマ アクティーゼルスカブ タンパク質チロシンキナーゼ阻害薬としての新規スルファミドピペラジン誘導体およびその医薬用途
WO2013016906A1 (zh) * 2011-07-29 2013-02-07 深圳光启高等理工研究院 人工复合材料和人工复合材料天线
PT2657233E (pt) * 2012-01-19 2014-10-24 Taiho Pharmaceutical Co Ltd Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal

Also Published As

Publication number Publication date
CA2946833C (en) 2019-03-05
SG11201608441YA (en) 2016-11-29
AU2015281155B2 (en) 2017-07-13
KR20170016510A (ko) 2017-02-13
AU2015281155A1 (en) 2016-11-03
RU2658008C2 (ru) 2018-06-19
BR112016025835A2 (enExample) 2017-08-15
CN106661031A (zh) 2017-05-10
CA2946833A1 (en) 2015-12-30
PL3103802T3 (pl) 2018-02-28
NO3103802T3 (enExample) 2018-04-07
US20170066772A1 (en) 2017-03-09
RU2016149319A3 (enExample) 2018-06-18
TW201625629A (zh) 2016-07-16
EP3103802A4 (en) 2017-03-08
PH12016502130B1 (en) 2016-12-19
CN106661031B (zh) 2019-07-23
JP6192741B2 (ja) 2017-09-06
MY183327A (en) 2021-02-18
AU2015281155B9 (en) 2017-11-16
BR112016025835B1 (pt) 2022-09-20
DK3103802T3 (en) 2017-12-11
US10174040B2 (en) 2019-01-08
US9963456B2 (en) 2018-05-08
WO2015199136A1 (ja) 2015-12-30
ES2656772T3 (es) 2018-02-28
HUE037266T2 (hu) 2018-08-28
JPWO2015199136A1 (ja) 2017-04-27
PH12016502130A1 (en) 2016-12-19
PT3103802T (pt) 2017-12-11
RU2016149319A (ru) 2018-06-18
US20180162864A1 (en) 2018-06-14
KR101947289B1 (ko) 2019-02-12
EP3103802B1 (en) 2017-11-08
MX2016015015A (es) 2017-02-27
EP3103802A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
TWI605048B (zh) Novel pyrrolopyrimidine compounds or salts thereof, and pharmaceutical compositions containing the same, in particular, prophylactic and / or therapeutic agents for tumors and the like based on the inhibition of NAE
TWI623316B (zh) Antitumor effect enhancer derived from pyrrolopyrimidine compound
JP6359546B2 (ja) Jak阻害薬としての三環式縮合チオフェン誘導体
CN109790122B (zh) 杂环化合物
JP6553825B2 (ja) 抗がん剤として有用な置換カルボヌクレオシド誘導体
TWI639602B (zh) 三環旋轉酶抑制劑
CN102459272B (zh) 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
RU2666349C2 (ru) Новое конденсированное пиримидиновое соединение или его соль
KR20140123104A (ko) 유비퀴틴 활성화 효소의 피라졸로피리미디닐 억제제
CN115403584A (zh) 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
CN107848971A (zh) 杂环化合物
HK1236948A1 (en) Pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, and applications
HK1236948B (zh) 毗咯并嘧啶化合物或其盐、含有其的药物组合物及应用
WO2022052926A1 (zh) 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用
TW202220978A (zh) 雜環化合物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees